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Background: DNA from buccal brush samples is being used for high-throughput analyses in a variety of
applications, but the impact of sample type on genotyping success and downstream statistical analysis remains
unclear. The objective of the current study was to determine laboratory predictors of genotyping failure among
buccal DNA samples, and to evaluate the successfully genotyped results with respect to analytic quality control
metrics. Sample and genotyping characteristics were compared between buccal and blood samples collected in
the population-based Genetic and Environmental Risk Factors for Hemorrhagic Stroke (GERFHS) study (https://
gerfhs.phs.wfubmc.edu/public/index.cfm).
Results: Seven-hundred eight (708) buccal and 142 blood DNA samples were analyzed for laboratory-based and
analysis metrics. Overall genotyping failure rates were not statistically different between buccal (11.3%) and blood
(7.0%, p = 0.18) samples; however, both the Contrast Quality Control (cQC) rate and the dynamic model (DM) call
rates were lower among buccal DNA samples (p < 0.0001). The ratio of double-stranded to total DNA (ds/total ratio)
in the buccal samples was the only laboratory characteristic predicting sample success (p < 0.0001). A threshold of
at least 34% ds/total DNA provided specificity of 98.7% with a 90.5% negative predictive value for eliminating
probable failures. After genotyping, median sample call rates (99.1% vs. 99.4%, p < 0.0001) and heterozygosity rates
(25.6% vs. 25.7%, p = 0.006) were lower for buccal versus blood DNA samples, respectively, but absolute differences
were small. Minor allele frequency differences from HapMap were smaller for buccal than blood samples, and both
sample types demonstrated tight genotyping clusters, even for rare alleles.
Conclusions: We identified a buccal sample characteristic, a ratio of ds/total DNA <34%, which distinguished
buccal DNA samples likely to fail high-throughput genotyping. Applying this threshold, the quality of final
genotyping resulting from buccal samples is somewhat lower, but compares favorably to blood. Caution is
warranted if cases and controls have different sample types, but buccal samples provide comparable results to
blood samples in large-scale genotyping analyses.
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Table 1 Patient and quality control characteristics by
sample type
N All Buccal Blood
850 708 (83%) 142 (17%)
Patient
Age (years ± SD) 66.7 ± 14.8 67.2 ± 14.8 64.6 ± 14.9
Sex (% male) 417 (49.1%) 348 (49.2%) 69 (48.6%)
Stroke status (% cases) 433 (50.9%) 353 (49.9%) 80 (56.3%)
Cigarette smoker
(% current)
163 (19.2%) 136 (19.2%) 27 (19.0%)
Pre-genotyping QC
QC Failure (%)a 90 (10.6%) 80 (11.3%) 10 (7.0%)
cQC <0.4 75 (8.8%) 69 (9.7%) 6 (4.2%)
DM call rate <83% 65 (7.6%) 60 (8.5%) 5 (3.5%)
Gender mismatch 24 (2.8%) 19 (2.7%) 5 (3.5%)
cQC rate 2.08 ± 0.94 2.00 ± 0.94 2.53 ± 0.82***
Among passed samples 2.33 ± 0.65 2.24 ± 0.65 2.69 ± 0.55***
Among failed samples 0.05 ± 0.43 0.01 ± 0.37 0.36 ± 0.71
DM call rate 93.1 ± 7.8% 92.7 ± 8.3% 95.1 ± 4.0% ***
Among passed samples 95.3 ± 2.8% 95.1 ± 2.9% 96.0 ± 1.9% ***
Among failed samples 74.7 ± 11.7% 73.5 ± 11.7% 83.9 ± 6.9% **
N (%) or mean ± SD presented.
a Failure subsets do not add to total failed samples, as samples frequently fail
for more than one reason.
** p < 0.01 blood vs. buccal samples; ***p < 0.0001 blood vs. buccal samples.
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Genetic studies involving high-throughput methods,
such as genome-wide association studies or sequencing,
are increasingly important and often rely on large
cohorts of participants or patients. In the context of
large genetic epidemiologic studies, DNA derived from
buccal cells has the advantage of being readily mailed
to remote regions whereas a blood draw frequently
requires an in-person contact, and buccal collection
may result in higher subject participation [1]. While
newer options, such as saliva collection, offer high-
quality non-invasive methods for collecting DNA [2,3],
many older epidemiologic studies, as well as a variety
of other applications such as forensics, rely on buccal
DNA samples for genetic analysis [4,5]. The primary
concern about buccal samples is that they may be more
likely to fail genotyping, either due to low yield or
lower or more variable quality of DNA. Several studies
have explored the quantity and quality of DNA
extracted from buccal samples, with mixed conclusions
about their utility [3,4,6-10].
Sample and processing metrics to predict buccal DNA
sample failure and improve genotyping quality are there-
fore essential. Additionally, no studies to our knowledge
have examined the impact of sample type on estimates
of allele frequency or other metrics likely to directly im-
pact statistical analysis and interpretation of high-
throughput genetic studies. Our group has previously
explored the yield and utility of buccal DNA samples in
the context of high-throughput SNP genotyping [11],
and has shown that buccal DNA provide reasonable
yields and concordance with paired blood samples.
Other studies have also shown success with buccal-
derived DNA in this context [12,13]. However, our pre-
vious study was limited in scope and used genotype call
rates and concordance rates as the only quality control
metrics.
The objective of the current study, therefore, is to
determine methods for predicting which buccal DNA
samples are likely to provide unacceptable genotyping
results, and to evaluate the performance of successful
buccal genotyping with respect to factors important
for correct statistical analysis and interpretation of the
resulting data. We report that buccal DNA samples
with <34% double-stranded DNA (dsDNA) to total
DNA were 18 times more likely to fail than samples
with ≥34% dsDNA. Also, we report that buccal samples
exhibited lower call rates than blood samples; but sam-
ples that passed QC had high quality genotype clustering
and exhibited minor allele frequency estimates compar-
able to HapMap. Taken together, these results indicate
some loss of statistical power but minimal statistical bias
when using these samples in high-throughput genetic
studies.Results
Comparisons of subject and sample characteristics by
sample type are presented in Table 1. Buccal samples
and blood samples did not differ with respect to the sub-
ject’s age (p = 0.07), gender (p = 0.9) or stroke status
(p = 0.17), as expected given the matched study design
and balanced sample plating design. The sample types
also did not differ on subjects’ cigarette smoking status
(p = 1.0), cigar smoking (p = 1.0) or frequency of alcohol
use (p = 0.3; data not shown). Average daily intake of caf-
feinated beverages likewise did not differ by sample type
(coffee: p = 0.6, tea: p = 0.08; soda: p = 0.98).
Quality control metrics differed somewhat between
blood and buccal samples (Table 1). Overall failure rates
did not differ significantly (11.3% buccal, 7.0% blood,
p = 0.18), and the proportion of samples that met any
specific failure threshold also did not significantly differ
by sample type (cQC failure, p = 0.06; DM call rate fail-
ure, p = 0.13; gender mismatch, p = 0.4). However, buccal
samples exhibited lower average cQC rates (p < 0.0001)
and DM call rates (p < 0.0001) than blood samples. Inter-
estingly, successful buccal samples had lower cQC rates
(p < 0.0001) and DM call rates (p < 0.0001) than success-
ful blood samples. Similarly, failed buccal samples also
had lower DM call rates than failed blood samples
(p < 0.01), which suggests an overall downward shift in
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samples.Phase I: Predicting pre-genotyping QC failure in Buccal
samples
Considering all sample quality and quantity variables;
time between sample collection and genotyping; and
relevant patient lifestyle factors (Table 2), lower ds/total
DNA ratio was significantly (p < 0.0001) associated with
buccal sample failure, while higher total DNA concen-
tration was marginally associated (p = 0.05). Failed buccal
samples were also collected more recently than those
that did not fail (p < 0.0001). Because higher total DNA
concentration helps define ds/total DNA ratio but was
less strongly associated, we limited further analysis of
buccal sample failure to ds/total DNA ratio and time
since sample collection.
From logistic regression analyses, each 10% absolute
increase in ds/total DNA ratio (e.g., from 20% to 30%) is
associated with a 40% lower odds of sample failure
(OR= 0.61, 95% CI = 0.52–0.70, p < 0.0001), with a sig-
nificant area under the ROC curve of 0.74 (95% confi-
dence interval: 0.67–0.80, p < 0.0001). Importantly, the
probability of sample failure increased significantly with
very low ds/total ratios (Figure 1). Years since sample
collection was significant when added to this logistic
model (OR= 0.86, 95% CI = 0.77-0.95, p = 0.004), but did
not materially alter the findings for ds/total DNA ratio
(OR= 0.62, 95% CI = 0.55-0.72, p < 0.0001; ROC AUC=
0.75). Using this analysis, we established a threshold of
ds/total ratio ≥ 0.34 during the study to determine which
samples should be processed, which balanced sensitivity
for failure of 20.5% with specificity for failure of 98.7%
in the first 3 plates run. Overall, samples with ds/totalTable 2 Predictors of quality control failure among buccal sam
N All buccal QC passed
708 628
Years since sample collection 7.9 [5.3, 10.0] 8.0 [5.6, 10.
Current cigarette smoker (%) 136 (19.2%) 116 (18.5%
Current cigar smoker (%) 21 (3%) 17 (2.7%)
Average daily coffee intake (cups) 1.43 (1.28, 1.59) 1.39 (1.23, 1.
Average daily tea intake (cups) 0.42 (0.33, 0.51) 0.42 (0.32, 0.
Average daily sodas 0.75 (0.62, 0.87) 0.74 (0.60, 0.
260/280 Ratio 1.81 (1.80-1.81) 1.81 (1.80-1.
260/230 Ratio 1.17 (1.15- 1.20) 1.18 (1.15-1.
Total DNA (ng/μl)a 87.4 (82.3-92.8) 85.6 (80.6-91
ds DNA (ng/μl)a 55.7 (52.5-59.1) 56.8 (53.5-60
ds/total DNA ratio 0.66 (0.65-0.68) 0.68 (0.67-0.
Mean (95% confidence limits of mean) or n (%) presented; median [interquartile ran
a Back-transformed from log values (geometric mean).ratio ≥ 0.34 experienced a 9.5% failure rate (63 of 662),
compared with a 65% failure rate (15 of 23) among those
that did not meet the ds/total DNA threshold (OR=
17.8, 95% CI: 7.3–43.7, p < 0.0001; Table 3). By contrast,
the higher “optimal” threshold ds/total ratio of ≥0.58
(70.5% sensitivity and 69.7% specificity) would have
reduced the QC failure rate to 5.5%, but adoption of this
threshold would have resulted in the elimination of 34%
of our buccal samples, 77% (180/233) of which would ul-
timately have passed QC.Phase II: Buccal versus blood genotype quality
Among samples that passed initial QC, sample call rates
were modestly but significantly lower for buccal com-
pared with blood DNA samples [Median (Interquartile
Range, IQR): 99.1 (98.4, 99.5)% buccal vs. 99.4 (99.1,
99.8)% blood, p < 0.0001] (Figure 2). Heterozygosity rates
were slightly but significantly lower in buccal samples
for both male [Median (IQR): 25.6 (25.4, 25.8)% buccal
vs. 25.7 (25.5, 25.9)% blood, p = 0.006; Figure 3A] and fe-
male samples [26.5 (26.4, 26.7)% buccal vs. 26.6 (26.5,
26.9)% blood, p = 0.001; Figure 3B].
Of the 906,600 SNPs on the Affymetrix 6.0 chip,
755,837 (83%) had a MAF <40%. Overall, MAF for both
buccal and blood samples were similar to estimates from
CEU HapMap standards. Figure 4A shows the corres-
pondence between buccal and blood sample deviations
from CEU HapMap MAF. Overall, median MAF did not
differ from HapMap for both blood and buccal samples
(e.g., median absolute difference = 0), but blood samples
had higher variability (IQR=−2% to +3% in blood, -1%
to +2% in buccal). Figure 4B provides the deviation of
our samples from the CEU MAF by sample type and






0] 5.3 [4.2, 9.0] <0.0001 <0.0001
) 20 (25%) 0.16 0.18
4 (5%) 0.26 0.28
54) 1.79 (1.16, 2.42) 0.23 0.25
51) 0.42 (0.19, 0.66) 0.96 0.77
87) 0.85 (0.54, 1.16) 0.50 0.06
81) 1.82(1.80-1.84) 0.42 0.32
21) 1.14 (1.06-1.21) 0.38 0.39
.8) 102.5 (87.4-121.5) 0.06 0.05
.3) 49.4 (41.3-59.1) 0.12 0.09
69) 0.52 (0.46-0.57) <0.0001 <0.0001
ge] presented for years since sample collection.
Figure 1 Probability of sample failure by ds/total DNA ratio. Predicted probability of sample pre-genotyping failure from logistic regression
analysis. Line represents predicted probability and shaded area is 95% confidence limits.
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interquartile ranges extending as far as 5% different from
CEU. Typically, blood samples demonstrated slightly
greater differences from CEU than buccal samples. Des-
pite IQRs that included no difference, all comparisons of
MAF overall or by MAF group were significant at
p < 0.0001 due to very large numbers of loci included in
estimates (>17,000 SNPs included in each MAF group).
Visual review of cluster plots did not reveal any system-
atic difference between sample types for any MAF cat-
egory (Figure 5).
Discussion
The results of this study demonstrate that applying a
minimum threshold for the ratio of double-stranded to
total DNA quantity can improve the likelihood of suc-
cessful genotyping for buccal DNA samples. Further-
more, applying this minimal level of quality control
results in buccal genotyping results that are only slightly
lower than the gold standard of blood DNA. This study
also suggests specific additional considerations that may
further improve results from buccal samples. Overall, weTable 3 Sensitivity and specificity of ds/total DNA ratios to de
ds/total DNA
ratio threshold
N (%) of samples
meeting threshold
Sensitivity
<0.34 23 (3.3%) 20.5%
<0.58 223 (34.0%) 70.5%have shown that buccal samples not only can be success-
fully genotyped, but also provide high quality analytic
data suitable for large-scale or high-throughput genetic
studies.
The major finding of this study is that it is important
to monitor ds/total DNA ratio to identify buccal samples
at high likelihood of failure. In this study, low ds/total
DNA ratio was a significant independent predictor of
pre-genotyping failure, assuming acceptable 260/280 and
260/230 ratios. In this study, buccal samples drawn more
recently were also more likely to fail, contrary to expec-
tations, but time since sample collection did not alter
the effects of ds/total DNA ratio in our analysis. Reasons
for this finding are unclear, but may be driven statisti-
cally by a gap of over a year in which recruitment was
dormant (e.g., artificially making the differences between
the medians larger), as study protocols and staffing were
consistent throughout the study. These results, however,
suggest that longer cryogenic storage times do not nega-
tively impact buccal DNA quality. The threshold of 34%
ds/total DNA was selected to provide good discrimina-







Figure 2 Call rates by sample type. Histogram and smoothed spline of sample call rates by sample type.
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those meeting it. Application of this QC standard thus
prevented the unnecessary running of samples on ex-
pensive chips if their likelihood of failure was signifi-
cant, while retaining maximal sample size. This
threshold may not be universally applicable to all stud-
ies depending on measurement of DNA concentration
and laboratory techniques, but should be considered
for studies conducting high-throughput genotyping
using buccal-derived DNA.
In this large study, buccal samples had similar overall
pre-genotyping failure rate, but lower cQC and lower
DM call rates than blood samples, suggesting a shift
toward lower overall quality. The similarity in overall
failure rate may be somewhat optimistic, as buccal
sample selection in the last 70% of this study was
intentionally shifted toward those most likely to pass
QC (e.g., ≥34% ds/total DNA); extracted samples below
this threshold were not included in genotyping runs
after the 3rd plate. The current analysis suggests that
buccal samples may require higher QC thresholds to
ensure that cQC and DM quality metrics are compar-
able to blood samples, particularly for the DM call
rate, which was lower for both passed and failed buc-
cal samples compared with the blood samples. There
is precedent for subjecting different “populations” of
samples or loci to different thresholds to improve per-
formance, which has shown promise in previous situa-
tions [14]. However, establishing higher thresholdswould result in the rejection of more buccal samples
in the QC phase, limiting sample size.
Birdseed genotyping results from passed samples were
comparable for buccal and blood samples. Although all
results were statistically better among blood samples,
the magnitude of the differences are frequently nominal.
This is consistent with a previous analysis of paired buc-
cal and blood samples in this study that revealed similar
call rates and 98.8% concordance of genotyping calls be-
tween buccal and blood samples, indicating high fidelity
of genotyping across sample type [11]. Median call rates
were high for both sample types (>99%) and deviations
from HapMap minor allele frequencies for Caucasian
populations were similarly minor. Analysis of MAF
deviations showed similar patterns, even for rare SNPs
that are frequently ignored in genetic studies for concern
over accurate genotype calling. However, all MAFs esti-
mated for this study deviated positively from HapMap
estimates, which may be due to regional differences in
population compared with the CEU HapMap. The over-
estimation of MAF may also suggest the presence of
missing call bias where no-calls are more likely in one
genotype than another [14], although this effect appears
similar for buccal and blood samples. Visual inspection
of cluster plots revealed no obvious issues, with distinct
clusters and minimal no-calls for both sample types,
even for SNPs of low MAF. Furthermore, the median
test revealed no batch effects on estimated MAF by
locus across plates (data not shown). However, the
Figure 3 Heterozygosity rates by sample type and sex. Smoothed spline of heterozygosity rates calculated across all chromosomes, by
sample type and sex for A) males and B) females. Heterozygosity rates for females are higher on average than males due to inclusion of X
chromosome loci.
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cantly lower than the blood samples (data not shown),
which suggests that buccal samples and blood samples
should be clustered separately for accurate genotyping.
These similarities between buccal and blood samples
suggest that both sample types can be used in high-
throughput genetic studies with only minor caveats.
However, with the increasing use of “out of study” con-
trols in large-scale genetic studies, these minor differ-
ences may be magnified. In particular, when cases andcontrols are derived from different sample types (e.g.,
cases are buccal DNA, while controls are blood DNA),
differences in sample failure rates, call rates and MAF
estimation between buccal and blood samples may result
in spurious false-positive associations with disease status
[14]. It is thus imperative that sample types match be-
tween cases and controls, or are at least represent a bal-
ance of sample types in both groups.
There are several important strengths of this study. A
large number of samples were evaluated in the context
Figure 4 (See legend on next page.)
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Figure 4 MAF by sample type compared with CEU HapMap. Panel A: Distributions and scatter plot of minor allele frequency (MAF)
deviations from CEU HapMap reference by locus and sample type. Box plot represents overall deviation from the HapMap by sample type.
Horizontal line represents median deviation, top and bottom box boundaries delineate the 25th and 75th percentiles (IQR) and whiskers extend to
1.5 times the IQR above and below the box. Panel B: MAF deviations by sample type, clustered by HapMap MAF categories. Box plots are
constructed as in Panel A.
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cessed by the same laboratory personnel. Plates were
constructed to incorporate both cases and matched con-
trols of the same sample type on the same plate, and col-
lection of buccal samples was conducted by trained
study nurses using standardized protocols. Despite these
significant strengths, this study also has certain limita-
tions. The present analysis does not include paired buc-
cal and blood samples from the same individuals, so we
cannot determine concordance in genotyping between
sample types. However, our previous study in the same
population suggested buccal DNA provide reasonable
concordance with paired blood samples [11]. Also, iden-
tification of the ds/total DNA ratio threshold was con-
ducted in the course of the genotyping, which changed
the decision about which samples would be genotyped
in the remainder of study. Thus, it was not possible to
fully evaluate whether the 34% threshold is optimal, or
whether a different threshold would have been better if
all samples had been run blinded to ds/total DNA ratio.Conclusions
Overall, buccal samples did not demonstrate significantly
worse QC failure rates than blood samples, although
some metrics show worse performance. Following strin-
gent QC, the quality of final genotyping resulting from
buccal samples is somewhat lower, but compares favor-
ably to blood. There is no evidence for differential loss
of information or bias with respect to genotype calling
from buccal vs. blood DNA samples. We recommend
using caution, but not doubt, when conducting high-
throughput genetic studies with buccal samples.Methods
The Genetic and Environmental Risk Factors for
Hemorrhagic Stroke (GERFHS) study is a large case–
control study of hemorrhagic stroke in the Cincinnati,
Ohio region. To maximize participation and representa-
tiveness of the cohort, buccal cytobrush collection was
performed on the majority of subjects. Buccal brushes
for genetic analysis were collected between 1997 and
2005, blood samples were collected for some subjects
from 2000 to 2005, and blood was collected on all sub-
jects after 2005. Each study participant included in this
analysis had either a buccal sample or a blood sample
genotyped, but not both. The GERFHS study employeda matched case–control design, with matching on age
(±5 years), sex, and race; controls were also selected to
have the same sample type (buccal or blood DNA sam-
ples) as their matched case whenever possible. All indivi-
duals included in this analysis were non-Hispanic white.
Buccal brushes were collected on each participant
using CYTO-PAK Cytosoft Brushes (Medical Packaging
Corp., Camarillo, CA). Study research nurses were
trained to collect buccal cytobrush samples in a standar-
dized fashion, as previously described [11]. Blood sam-
ples were drawn by hospital nursing personnel using two
10 ml purple-top tubes with EDTA solution from sub-
jects during their hospital stay. Controls were recruited
from the community using random-digit dialing. This
study protocol was approved by the Institutional Review
Boards of the University of Cincinnati and all participat-
ing hospitals, and all subjects provided written informed
consent for genetic testing.DNA extraction and genotyping
Both blood and buccal cell DNA were extracted using
PureGene DNA extraction kits specific to sample type
(Gentra Systems, Inc. Minneapolis, MN), according to
manufacturer directions. Briefly, the extraction for buc-
cal DNA was as follows: buccal brushes were cut and
placed into a microfuge tube containing cell lysis solu-
tion and proteinase K, and incubated overnight at 55°C.
After cooling, protein precipitation solution was added,
vortexed and centrifuged. The supernatant was trans-
ferred to a tube containing isopropanol and glycogen so-
lution, incubated at room temperature, and centrifuged.
The DNA pellet was washed with 70% ethanol and air
dried. TE buffer was added and incubated at 1 hour at
65°C prior to storage at −20°C.
The total concentration, 260/280, 260/230 ratios of
genomic DNA for all samples were measured using a
spectrophotometer (NanoDrop ND-1000, NanoDrop
Technologies). Finally, double-stranded DNA (dsDNA)
concentration was measured using the Quant-it dsDNA
BR assay kit and Qubit fluorometer (Invitrogen). All
DNA samples were normalized to 50 ng/μl dsDNA in
reduced EDTA TE buffer. Samples that did not meet
260/280 ratio of at least 1.7 and 260/230 ratio of at least
1.0 were not included in genotyping.
Cases and their matched controls were arrayed on the
same plates, and their genotypes called at the same time.
Figure 5 Cluster plots by MAF and sample type. Three SNPs meeting Hardy-Weinberg expectations (p > 0.24) were randomly selected for
visual presentation, representing differing MAF classes. A) rs16933208 (MAF= 0.98%); B) rs12598047 (MAF= 2.88%); C) rs11803463 (MAF= 21.6%).
Buccal-1 and Buccal-2 columns present clusters from two different plates of buccal samples, while the Blood column presents clusters from a
plate of blood samples.
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Scanner 3000 platform using Human SNP Array 6.0.
The recommended protocol as described in the Affyme-
trix manual was followed. Five μl (250 ng) of dsDNA
was digested with Sty I and ligated to Sty I adapters
using T4 DNA ligase. Another 5 μl (250 ng) of dsDNA
was digested with NspI and ligated to Nsp I adapters
using T4 DNA ligase. Two digested samples were then
PCR amplified individually using TITANIUM DNA
amplification kit (Clontech) on an ABI9700 machine.
PCR products were pooled and purified using the Agen-
court AMPure magnetic beads (Beckman Coulter) and
96-well filter plate (E&K Scientific) followed by fragmen-
tation and labeling. Samples were then injected into car-
tridges, hybridized, washed, and stained. Mapping arrayimages were obtained using the GeneChip Scanner 3000
with GCOS software. Image files were uploaded to
the Cincinnati Children’s Hospital Medical Center
(CCHMC) Genotyping Data Repository in 10 batches
of ~96 samples per batch. Samples were determined
to be initial QC failures if they failed to meet the de-
fault Birdseed (v. 1.12.0) QC thresholds of Contrast
Quality Control (cQC) > 0.4, Dynamic Model (DM)
call rate >83%, or were gender mismatches based on
actual versus inferred gender. A subset of samples
that failed initial QC were re-extracted and/or re-
hybridized in an attempt to recover the sample; how-
ever, this rarely resulted in sample recovery. Samples
that failed initial QC were excluded from full geno-
typing with Birdseed clustering. Birdseed genotyping
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results were evaluated for evidence of batch effects
using the median test, and results were not different
by batch.
Analysis design
All data analysis was conducted using SAS v.9.2 (SAS In-
stitute, Cary, NC). Descriptive characteristics between
participants with buccal versus blood samples were com-
pared using parametric t-tests, non-parametric Wilcoxon
rank sum, χ2 analyses, or Fisher’s Exact tests, as appro-
priate to the distribution of the variable.
The statistical evaluation of DNA performance was
partitioned into two phases. The first phase was
designed to evaluate the role of time since sample col-
lection; relevant patient lifestyle (e.g., smoking or drink-
ing alcohol or caffeinated beverages); and quantitative
laboratory-based sample metrics for the ability to
discriminate buccal DNA samples likely to fail pre-
genotype calling quality control (QC) screening. Iden-
tification of independent predictors of sample failure
was conducted in real-time (during the course of ac-
tive genotyping) using data from the first three batches
of samples (n = 270 buccal samples). Thresholds were
established and then applied to the remaining samples
run after that point. After the conclusion of all geno-
typing, analyses were conducted to compare QC
metrics between buccal and blood samples and to cal-
culate failure rates based on the previously established
thresholds. This analysis sample set included results
from both successful and failed buccal and blood sam-
ples, limited to one result per unique individual
(n = 850) to avoid inflation of sample failure due to
failed repeat hybridizations for some samples.
For this first phase of analysis, the dependent variable
was success or failure of buccal DNA to pass pre-
genotyping QC metrics. Independent variables for the
first phase included the time between sample collection
and genotyping; relevant patient lifestyle variables
(current cigarette smoking, current cigar smoking, fre-
quency of alcohol use, average daily intake of caffeinated
coffee, tea or soda); and the quantity (total DNA concen-
tration, dsDNA concentration, ds/total DNA ratio) and
quality (260/280 and 260/230 ratios) of extracted DNA.
Each variable was examined for outliers, and variables
with excessive skewness or kurtosis (<−1 or >1) were
natural log transformed to improve normality; both total
DNA and dsDNA concentration were thus analyzed in
log-transformed units. Because of differences in meas-
urement method and sensitivity between the Nanodrop
and Qubit DNA quantitation techniques, ds/total DNA
ratios occasionally exceeded 1.0. Buccal DNA sample
characteristics between samples that passed initial QC
versus those that failed were compared using Wilcoxonrank sum statistics (for continuous variables) or Fisher’s
Exact Test (for categorical variables). Logistic regression
was used to construct receiver operator characteristic
(ROC) curves and establish thresholds of significant
variables to distinguish initial QC success from failure.
The second phase of analysis was designed to test the
performance of buccal versus blood DNA samples that
passed initial QC. Metrics for this analysis included sam-
ple call rate, minor allele frequency (MAF) comparisons
between buccal and blood samples in reference to Cau-
casian (CEU) HapMap samples, and average heterozy-
gosity rates. Heterozygosity rates were calculated
separately by sex across all chromosomes. Call rates and
heterozygosity rates between buccal and blood samples
were compared using Wilcoxon Signed Rank tests.
Low MAF can influence the performance of the clus-
tering algorithms for calling genotypes. Absolute differ-
ences between buccal or blood MAF and the CEU
reference were analyzed using Wilcoxon Signed Rank
tests. In addition, we explored the effect of specific MAF
categories (MAF < 0.5%, 0.5%–1.5%, 1.5%–2%, 2%–5%,
5%–10%, 10%–15% and 15%–40%) on the deviation of
buccal or blood sample MAF from the CEU HapMap
standard. MAF categories were established based on the
CEU HapMap reference, with MAF >40% excluded from
analysis to minimize the likelihood that the minor allele
in HapMap would be the major allele in our population.
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